[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633427":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":68,"centralContacts":74,"locations":80,"responsibleParty":97,"collaborators":99,"id":105,"slug":47,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":47,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":47,"overallStatus":125,"whyStopped":47,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"University of Michigan Rogel Cancer Center","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm I (MPS2)","EXPERIMENTAL","Patients undergo urine sample collection for MPS2 testing. Patients' treating physicians review and utilize the results of the MPS2 test to determine if patients undergo SOC MRI and\u002For biopsy.",[13,14,15,16],"Procedure: Biopsy Procedure","Device: Diagnostic Procedure","Other: Electronic Health Record Review","Procedure: Magnetic Resonance Imaging",{"label":18,"type":19,"description":20,"interventionNames":21},"Arm II (MPS2)","ACTIVE_COMPARATOR","Patients undergo urine sample collection for MPS2 testing. Patients' treating physicians do NOT review or utilize results of the MPS2 test to determine if patients undergo a biopsy after SOC MRI.",[13,14,15,16],[23,32,43,48],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"PROCEDURE","Biopsy Procedure","Undergo biopsy",[9,18],[29,30,31],"Biopsy","BIOPSY_TYPE","Bx",{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DEVICE","Diagnostic Procedure","Undergo MPS2 urine test",[9,18],[38,39,40,41,42],"Diagnostic","Diagnostic Method","Diagnostic Technique","Diagnostic Test","Evaluation Basis of Disease Status",{"type":6,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"Electronic Health Record Review","Ancillary studies",[9,18],null,{"type":24,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"Magnetic Resonance Imaging","Undergo MRI",[9,18],[53,54,55,56,57,58,59,60,61,62,63,64,65,66,67],"Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance \u002F Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI",[69,72],{"name":70,"affiliation":5,"role":71},"Udit Singhal, MD","PRINCIPAL_INVESTIGATOR",{"name":73,"affiliation":5,"role":71},"Todd Morgan, MD",[75],{"name":76,"role":77,"phone":78,"phoneExt":47,"email":79},"Uprise StudyTeam","CONTACT","734-615-6662","uprise-spore@med.umich.edu",[81],{"facility":5,"status":47,"city":82,"state":83,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"Ann Arbor","Michigan","48109","United States","US",{"type":88,"coordinates":89},"Point",[90,91],-83.74088,42.27756,{"lat":91,"lon":90},[94,95,96],{"name":76,"role":77,"phone":78,"phoneExt":47,"email":79},{"name":70,"role":71,"phone":47,"phoneExt":47,"email":47},{"name":73,"role":71,"phone":47,"phoneExt":47,"email":47},{"type":98,"investigatorFullName":47,"investigatorTitle":47,"investigatorAffiliation":47,"oldNameTitle":47,"oldOrganization":47},"SPONSOR",[100,103],{"name":101,"class":102},"National Institutes of Health (NIH)","NIH",{"name":104,"class":102},"National Cancer Institute (NCI)","100633427",false,"NCT07526545","Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial","UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)","UPRISE","Inclusion Criteria:\n\n* Males aged 50-75\n* PSA 3-20 ng\u002Fml within the previous 3 months\n* Fit to undergo all procedures listed in protocol per treating physician's discretion\n* No prostate biopsy in the past 4 years\n* No prostate MRI in the past 2 years\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Prior diagnosis of prostate cancer\n* Contraindication to MRI (e.g. claustrophobia, pacemaker)\n* Contraindication to prostate biopsy\n* Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work",true,"MALE","50 Years","75 Years",{"count":117,"type":118},800,"ESTIMATED","INTERVENTIONAL",[121],"NA","This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.",[124],"Prostate Carcinoma","NOT_YET_RECRUITING","2026-06-08",{"date":128,"type":129},"2026-06-09","ACTUAL",{"date":131,"type":118},"2026-09-01",{"date":133,"type":118},"2030-03-01",{"name":5,"class":6},1]